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ABSTRACT
Introduction: Guidelines for self-treatment of
hypoglycaemia specify initial treatment with
quick-acting carbohydrate until blood glucose
levels normalize and then follow-up with
longer-acting carbohydrate. The few studies
investigating follow-up show 29–57% omission
or undertreatment with follow-up carbohydrate
but do not investigate the association of this
with repeat hypoglycaemia. This study aimed
to develop, validate and administer a
questionnaire to delineate this association.
The timeframe targeted was 2 h post primary
hypoglycaemic event (PPHE), the time
influenced by long-acting carbohydrate.
Methods: A questionnaire was generated, test–
retest reliability assessed, and it was piloted on
convenience samples from the target
population. The final version was administered
to all insulin-treated individuals attending an
outpatient diabetes clinic over 4 weeks (169).
Results: Questionnaire development:
readability (69.6—standard/easy), test–retest
reliability (Cohen’s kappa 0.57–0.91) and
return rate (72.2%) were all acceptable.
Questionnaire data: questionnaires were
returned by 122 participants (63 males/59
females). Method of insulin administration
was subcutaneous insulin injections (91%) and
continuous subcutaneous insulin infusion
(CSII) (9%). Repeat hypoglycaemia within 2 h
PPHE was reported by 8.2% of respondents.
There was no significant difference for age,
gender and diabetes duration between those
reporting repeat hypoglycaemia and those
without. Consumption of follow-up longer-
acting carbohydrate was reported by 58.2% of
responders with 48% of these using long-acting
and 52% medium-acting carbohydrate foods.
Method of insulin administration and
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consumption of follow-up food were
significantly associated with repeat
hypoglycaemia (P = 0.015, 0.039) but presence
or absence of symptoms and duration of
action of carbohydrate were not significantly
associated (P = 0.103, 0.629). Hierarchical
logistic regression analysis showed omission of
follow-up food PPHE was not a significant
predictor of increased likelihood of repeat
hypoglycaemia within 2 h PPHE, irrespective
of method of insulin administration
(P = 0.085).
Conclusion: This study supports guidelines that
recommend judicious, rather than routine use
of follow-up longer-acting carbohydrate PPHE.
Keywords: Repeat hypoglycaemia; Insulin-
treated diabetes; Follow-up carbohydrate
INTRODUCTION
Hypoglycaemia is a common complication of
insulin treatment resulting from relative
insulin excess and suboptimal glucose
counterregulation [1]. Mean rates of
hypoglycaemia in insulin-treated diabetes are
reported as 42.89 (type 1) and 16.37 (type 2)
events per person per year (population-based
study) [2] and 29.0 (type 1 [15 years duration)
and 10.2 (type 2 [5 years duration) events per
person-year (secondary health based study) [3].
Hypoglycaemia is cited as the main impediment
to euglycemia [4] and the most feared
complication of insulin-treated diabetes [5].
It has been reported that 90.8% of adults
with type 1 and 84.5% with type 2 diabetes
self-treat their hypoglycaemia [6].
Recommendations for self-treatment advise
ingestion of quick-acting carbohydrate,
reassessment of blood glucose and repeat
treatment until blood glucose levels normalise.
Subsequent ingestion of longer-acting
carbohydrate is then recommended [7–14] as
quick-acting carbohydrate used for initial
treatment peaks at 30 min and may return to
baseline by 90–120 min [15], theoretically
increasing the possibility of a repeat
hypoglycaemic event within this timeframe.
Longer-acting carbohydrate potentially stays
above baseline to 210 min post-ingestion [16].
There are few reports in the literature on
the extent of adherence to recommendations
for follow-up treatment with longer-acting
carbohydrate [17–19]. Sommerfield et al. in a
survey of 101 insulin-treated individuals
reported 29% undertreating with long-acting
follow-up food [17], defining undertreatment as
less than 10–20 g of long-acting carbohydrate
(Diabetes UK Treatment Guidelines For
Hypoglycaemia) [13]. Sumner et al. surveyed
125 individuals with type 1 diabetes reporting
57% omitted long-acting follow-up
carbohydrate [18], and Vindedzis et al.
reported 44.2% omitted follow-up
carbohydrate in a survey of 119 insulin-treated
individuals [19]. The association of omission or
inadequate ingestion of follow-up food with
repeat hypoglycaemia was not investigated in
any of these studies.
Repeat hypoglycaemia per se does not have a
formal definition, and the term is sometimes
used interchangeably with recurrent
hypoglycaemia [20] and multiple episodes of
hypoglycaemia [21]. Current literature on
repeat/recurrent hypoglycaemia examines a
longer timeframe than would be affected
by lack of follow-up food post-primary
hypoglycaemic event (PPHE). Reports on
paramedic treatment of hypoglycaemia
identify repeat hypoglycaemia as occurring
within 24–72 h PPHE [22], and reviews of
mechanisms and prevention of hypoglycaemia
identify repeat hypoglycaemia over 24 h PPHE,
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or longer [23, 24]. This timescale for recurrence
in the insulin-treated individual will be largely
influenced by insulin status and also defective
counterregulation, clinically indicated by
reduced awareness of hypoglycaemic
symptoms [23]. Method of insulin
administration may be a modifier of
hypoglycaemia within a shorter timeframe;
there is mixed evidence of the association of
continuous subcutaneous insulin infusion
(CSII) with reduction in severe hypoglycaemia
as compared with multiple daily injections
[25, 26].
It could be reasonably assumed that the
effect of follow-up longer-acting carbohydrate
on blood glucose levels would be confined to
2–3 h PPHE depending on the source of the
carbohydrate [16]. We therefore hypothesized
that omission of follow-up longer-acting
carbohydrate would increase the frequency of
repeat hypoglycaemia within 2 h PPHE in free-
living insulin-treated individuals. The aim of
this study was therefore, first, to develop and
validate a questionnaire to obtain data on
treatment of primary hypoglycaemia, the
presence or absence of symptoms of
hypoglycaemia, and the frequency of repeat
hypoglycaemia within 2 h PPHE and second, to
administer this questionnaire to free-living
insulin-treated individuals to assess the
likelihood of repeat hypoglycaemia with and
without follow-up food while controlling for
other significant modifiers of hypoglycaemia.
MATERIALS AND METHODS
Development of the Questionnaire
The one-page questionnaire was couched in
simple language with explanation of technical
terms and aimed at completion within 10 min.
It commenced with a brief preamble assuring
anonymity and explaining the aim was
investigation of individual experience of
hypoglycaemia. Contact and ethics approval
details were provided. Questionnaire items were
generated from the literature, patient education
material and clinical experience and were a
mixture of multichoice and numeric and text
open-ended questions. Readability of the
questionnaire was assessed by the Flesch
Reading Ease Formula and Flesch–Kincaid
Grade Level Formula, which are considered
suitable for use in health care settings [27].
Content validity was assessed qualitatively by a
diabetologist, two diabetes educators and a
dietitian. A convenience sample of 19 insulin-
treated people from the population to be tested
were recruited to assess test–retest reliability of
the questionnaire, which was conducted by
comparing self-administered responses with
interview responses to the same questionnaire
items. Interviews were carried out by one of five
experienced diabetes educators blinded to the
original responses. The questionnaire was then
piloted on a convenience sample of nine people
with insulin-treated diabetes (7% of sample size)
to gain insight into item comprehension; this
resulted in several minor rewordings. The return
rate of the questionnaire was calculated by
number of returned questionnaires against
number distributed.
Administration of the Questionnaire
The questionnaire was distributed to all insulin-
treated adults attending routine outpatient
diabetes clinic appointments over a period of
4 weeks (n = 169). Treatment of diabetes was by
either subcutaneous insulin injection (SII) or
CSII. All procedures followed were in
accordance with the ethical standards of
the responsible committee on human
experimentation (institutional and national)
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and with the Helsinki Declaration of 1975,
as revised in 2000. Study information was
given and consent presumed on return of
questionnaire. Ethics approval was obtained
from Curtin University Human Research Ethics
Committee and the project was registered as a
clinical audit at Royal Perth Hospital. The
questionnaire was designed for self-
administration but was initially given to
insulin-treated individuals, with a brief
explanation, by one of five credentialled
diabetes educators. The questionnaire was
anonymous, filled out while waiting to see the
doctor and consent was presumed on return of
the questionnaire to a designated sealed box.
Statistical Methods
Questionnaire Development
Test–retest reliability of the questionnaire was
evaluated by percent agreement and also using
the kappa statistic (j), which measures the
amount by which agreement exceeds that
expected by chance. Kappa was calculated for
the self administered—interview data with 95%
confidence intervals based on 1,000 bootstraps.
Data from Questionnaire
Descriptive statistics were used for participant
characteristics and hypoglycaemic frequency.
The Chi-square test (v2) was used to compare
categorical variables and extended Fisher’s exact
test for age and duration of diabetes ([2 9 2
contingency table with some cells \5).
Glycaemic index (GI) was used to assess
duration of action of follow-up carbohydrate
with GI of B55 categorized as long-acting and
56–69 as medium-acting carbohydrate [28].
Hierarchical logistic regression analysis was
performed to predict the likelihood of repeat
hypoglycaemia with respect to consumption/
non-consumption of follow-up food while
controlling for other significant variables.
Analysis was performed using SPSS Statistics—
version 21 (IBM Corporation, Somers, NY, USA)




Readability of the questionnaire was assessed
as 69.6 on Flesch Reading Ease Formula
(standard—easy level) and 6.2 on Flesch–
Kincaid Grade Level Formula consistent with a
grade 6 level, thus theoretically understandable
by 85–90% of the population [27]. Test–retest
reliability and response rate for individual items
are shown in Table 1. Response rates and percent
agreement were uniformly high. Values for j
exceeded 0.61, indicating substantial agreement
for six of the seven questions, with moderate
agreement for the other [30].
Data from Questionnaire
Questionnaires were returned by 122 out of 169
participants (63 males, 59 females) giving a
return rate of 72.2%, well above the estimated
acceptable rate of 65% for self-completed postal
questionnaires [31]. Participant characteristics
are shown in Table 2 and self-reported frequency,
symptoms and treatment of hypoglycaemia in
Table 3. Repeat hypoglycaemia was reported by
8.2% (n = 10) of participants and correlated well
with a separate question on self-reported
frequency of repeat hypoglycaemia (P\0.001).
There was no significant difference in the
distribution of age, gender and duration of
diabetes between those reporting repeat
hypoglycaemia and those without (P = 0.343,
1.00, 0.458 respectively). All participants
reported consuming initial treatment food.
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Follow-up food ingestion was reported by
58.2% of item responders with 48% of these
using long-acting and 52% medium-acting
carbohydrate. Ninety percent of those using
medium-acting carbohydrate chose food
sources in the lower half of this category, i.e.
GI \62 (Fig. 1).
Both method of insulin administration and
consumption/non-consumption of follow-up
food PPHE were significantly associated with
presence/absence of repeat hypoglycaemia (v2:
P = 0.015, 0.039) but presence/absence of
hypoglycaemic symptoms and duration of
action of carbohydrate were not significantly
associated (v2: P = 0.103, 0.629). Hierarchical
logistic regression analysis was then conducted
to predict the likelihood of repeat
hypoglycaemia using consumption/non-
consumption of follow-up food PPHE as a
predictor variable while controlling for
method of insulin administration. A test of the
full model against a constant only model was
statistically significant, indicating that the
predictor variables should distinguish between
those with and without repeat hypoglycaemia
(v2 = 4.445, P = 0.035 with df = 1), the Hosmer–
Lemeshow goodness of fit test was not
significant (P = 0.838) indicating the model
prediction was not significantly different from
Table 1 Test–retest reliability and response rates of questionnaire items
Question topic Test–retest by interview % Item responseb
%a j 95% CI
Frequency of hypoglycaemia 94.7 0.91 0.71–1.00 97.5
Hypoglycaemic symptoms yes/no 78.9 0.69 0.39–0.92 94.3
Repeat hypoglycaemia yes/no 84.2 0.57 0.21–0.84 100
Frequency of repeat hypoglycaemia 94.7 0.89 0.63–1.00 100
Initial treatment food 88.9 0.84 0.60–1.00 100
Follow-up with food yes/no 89.5 0.76 0.53–1.00 98.4
Food used for follow-up 84.6 0.61 0.32–0.84 98.4
a Percent agreement
b Percent of total responders answering item
j Cohen’s kappa, CI conﬁdence interval
Table 2 Participant characteristics
Percent
responders
Gender (m/f) 63/59 100





Treatment (SII/CSII) (N, %) 111/11
(91/9)
100





CSII continuous subcutaneous insulin infusion, m/f male/
female, N number of responders, SII subcutaneous insulin
injection, y years
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the observed values; however, the Wald
criterion demonstrated that consumption/non-
consumption of follow-up food PPHE was not a
significant predictor of repeat hypoglycaemia
(P = 0.085). All standard errors \2 indicated no
multicollinearity between variables.
DISCUSSION
Insulin-treated individuals in the target
population are routinely taught to ingest
follow-up food post-hypoglycaemia; therefore,
it might be presumed they may be reluctant to
admit they do not carry this out. In view of this,
the data collection method considered optimal
for this study was an anonymous self-
administered questionnaire. This mode has
been shown to decrease biased responses and
result in more accurate and less ‘socially
desirable’ responses to sensitive health-related
questions than information obtained by
interview [32]. A negative aspect of self-
administered questionnaires is a possible
decrease in reliability for open and more
complex questions [33], but this was not
demonstrated in this study. Advanced
notification ahead of self-administration of a
questionnaire has been shown to raise response
rates and credibility without affecting
questionnaire response type [33], and the
initial contact by diabetes educators with









































wk week, y yes, n no, N number of responders
Fig. 1 Follow-up carbohydrate—foods ingested and
duration of action. Numbers in brackets in legend
(x) denote average GI. Slice labels denote percent
respondents ingesting speciﬁc food. Dotted slices denote
long-acting carbohydrate. Cross-hatched slices denote
medium-acting carbohydrate with GI\62
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potential participants may partly account for
the relatively high response rate.
Potentially many factors influence repeat
hypoglycaemia [23]. We have investigated one
of these (follow-up food) and sought to control
for the other factor (method of insulin
administration) that showed a significant
association within the specified timeframe.
Perhaps surprisingly, lack of symptoms of
hypoglycaemia was not a modifier, possibly a
function of the inclusion of individuals with
insulin-treated type 2 diabetes and the
associated lower rate of compromised
counterregulation [34].
A limitation of this study was the inability to
differentiate between type 1 and insulin-treated
type 2 diabetes. It was considered that self-
reported data on this may be inaccurate.
Similarly, we collected no data on alcohol
consumption, a modifier of hypoglycaemia, as
this requires strategies to obtain accurate
information outside the scope of this study [35].
Hierarchical binary logistic regression was
the statistical test of choice as it assesses the
likelihood of an event occurring given a set of
conditions and does not require the statistical
presumption of normality, which was not
fulfilled in this data as all variables were
categorical. Although only 10 participants
reported repeat hypoglycaemia, the sample
size (122) was considered adequate according
to the rule of thumb N - k - 1 C 50 (N = sample
size, k = number of predictor variables) [36].
The questionnaire item yes/no to experiencing
repeat hypoglycaemia was used as the outcome
variable, but only exhibited moderate
test–retest reliability. It did, however, show
excellent correlation with the separate
questionnaire item on frequency of repeat
hypoglycaemia, which exhibited high
test–retest reliability, and was therefore taken
as robust data.
The high reported rate (40.2%) of omission
of follow-up food in this study is consistent
with two other comparable studies [17, 19]. The
use of medium-acting foods for follow-up is
consistent with some recommendations [9, 13,
14], but notably, in this study, the majority of
respondents selecting medium-acting follow-up
foods tended towards those that were slower-
acting in this category and this may account for
the lack of association of duration of action of
carbohydrate with incidence of repeat
hypoglycaemia.
The relative percentages of reported repeat
hypoglycaemia and omission of follow-up
longer-acting carbohydrate PPHE suggest many
individuals do omit follow-up food with
impunity. The situation is rather complex,
with some guidelines recommending routine
consumption of follow-up food [7, 9, 12] and
others stating follow-up food may be required
[10, 13, 14]. CSII treatment is cited as one
instance where follow-up food may be
unnecessary as short-term insulin status is
more controllable [14]; however, in this study
omission of follow-up food PPHE did not
significantly increase the likelihood of repeat
hypoglycaemia irrespective of method of
insulin administration.
CONCLUSION
The results of this study support guidelines
recommending judicious, rather than routine
use of follow-up longer-acting carbohydrate
PPHE.
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